{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:40:51Z","timestamp":1790754051411,"version":"4.1.0"},"reference-count":40,"publisher":"Impact Journals, LLC","issue":"43","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,10,25]]},"DOI":"10.18632\/oncotarget.11904","type":"journal-article","created":{"date-parts":[[2016,9,8]],"date-time":"2016-09-08T17:56:40Z","timestamp":1473357400000},"page":"69625-69637","source":"Crossref","is-referenced-by-count":13,"title":["The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma"],"prefix":"10.18632","volume":"7","author":[{"given":"Kensuke","family":"Kojima","sequence":"first","affiliation":[{"name":"Department of Hematology, Respiratory Medicine and Oncology, Division of Medicine, Saga University, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Respiratory Medicine and Oncology, Division of Medicine, Saga University, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Respiratory Medicine and Oncology, Division of Medicine, Saga University, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nishida","sequence":"additional","affiliation":[{"name":"Department of Hematology, Respiratory Medicine and Oncology, Division of Medicine, Saga University, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Hematology, Respiratory Medicine and Oncology, Division of Medicine, Saga University, Saga, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,9,8]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","article-title":"Mantle Cell Lymphoma","volume":"34","author":"Wang","year":"2016","journal-title":"J Clin Oncol"},{"key":"2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2141.2008.07124.x","article-title":"Advances in the understanding of mantle cell lymphoma","volume":"142","author":"Campo","year":"2008","journal-title":"Br J Haematol"},{"key":"3","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Drach","year":"2015","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","article-title":"Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial","volume":"17","author":"Sandherr","year":"2016","journal-title":"Lancet Oncol"},{"key":"5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Radford","year":"2013","journal-title":"N Engl J Med"},{"key":"6","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S1470-2045(16)00027-9","article-title":"Immunomodulatory agents in mantle cell lymphoma","volume":"17","author":"Dunleavy","year":"2016","journal-title":"Lancet Oncol"},{"key":"7","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Post-ibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Noto","year":"2016","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Dreyling","year":"2015","journal-title":"Blood"},{"key":"9","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/1078-0432.CCR-08-0399","article-title":"MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma","volume":"15","author":"Raffeld","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1182\/blood-2005-12-5148","article-title":"Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia","volume":"108","author":"Andreeff","year":"2006","journal-title":"Blood"},{"key":"11","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/cas.12430","article-title":"Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma","volume":"105","author":"Kimura","year":"2014","journal-title":"Cancer Sci"},{"key":"12","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1078-0432.CCR-15-0481","article-title":"Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia","volume":"22","author":"Ruvolo","year":"2016","journal-title":"Clin Cancer Res"},{"key":"13","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1182\/blood.V126.23.258.258","article-title":"Safety, efficacy, and determination of the recommended phase 2 dose for the oral selective inhibitor of nuclear export (SINE) selinexor (KPT-330)","volume":"126","author":"Siegel","year":"2015","journal-title":"Blood"},{"key":"14","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/leu.2011.315","article-title":"Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia","volume":"26","author":"Gjertsen","year":"2012","journal-title":"Leukemia"},{"key":"15","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1182\/blood-2012-08-447581","article-title":"Prognostic impact and targeting of CRM1 in acute myeloid leukemia","volume":"121","author":"Kantarjian","year":"2013","journal-title":"Blood"},{"key":"16","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1038\/onc.2011.185","article-title":"Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3","volume":"30","author":"Maki","year":"2011","journal-title":"Oncogene"},{"key":"17","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1038\/cddis.2011.129","article-title":"Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells","volume":"2","author":"Mack","year":"2011","journal-title":"Cell Death Dis"},{"key":"18","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Clot","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"19","doi-asserted-by":"crossref","first-page":"7172","DOI":"10.1073\/pnas.1405663111","article-title":"Phosphatases reverse p53-mediated cell cycle checkpoints","volume":"111","author":"Donehower","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10555-008-9127-x","article-title":"The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways","volume":"27","author":"Donehower","year":"2008","journal-title":"Cancer Metastasis Rev"},{"key":"21","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s13277-014-2828-6","article-title":"PPM1D overexpression predicts poor prognosis in non-small cell lung cancer","volume":"36","author":"Jiang","year":"2015","journal-title":"Tumour Biol"},{"key":"22","doi-asserted-by":"crossref","first-page":"e110218","DOI":"10.1371\/journal.pone.0110218","article-title":"Overexpression of wip1 is associated with biologic behavior in human clear cell renal cell carcinoma","volume":"9","author":"Zu","year":"2014","journal-title":"PLoS One"},{"key":"23","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/modpathol.2010.121","article-title":"PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenichybridization study","volume":"23","author":"Reis-Filho","year":"2010","journal-title":"Mod Pathol"},{"key":"24","first-page":"1995","article-title":"Association of 17q21-q24 gain in ovarian clear cell adenocarcinomas with poor prognosis and identification of PPM1D and APPBP2 as likely amplification targets","volume":"9","author":"Imoto","year":"2003","journal-title":"Clin Cancer Res"},{"key":"25","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nchembio.1427","article-title":"Allosteric Wip1 phosphatase inhibition through flap-subdomain interaction","volume":"10","author":"Schaber","year":"2014","journal-title":"Nat Chem Biol"},{"key":"26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1158\/1535-7163.MCT-15-0651","article-title":"Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1\/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner","volume":"15","author":"Lunec","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"27","doi-asserted-by":"crossref","first-page":"e0115635","DOI":"10.1371\/journal.pone.0115635","article-title":"WIP1 phosphatase as a potential therapeutic target in neuroblastoma","volume":"10","author":"Kumar","year":"2015","journal-title":"PLoS One"},{"key":"28","doi-asserted-by":"publisher","first-page":"14458","DOI":"10.18632\/oncotarget.7363","article-title":"Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3","volume":"7","author":"Macurek","year":"2016","journal-title":"Oncotarget"},{"key":"29","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/ng1532","article-title":"Reverse engineering of regulatory networks in human B cells","volume":"37","author":"Califano","year":"2005","journal-title":"Nat Genet"},{"key":"30","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Hurt","year":"2003","journal-title":"Cancer Cell"},{"key":"31","first-page":"a000935","article-title":"Transcriptional regulation by p53","volume":"2","author":"Prives","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"32","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/leu.2008.348","article-title":"Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma","volume":"23","author":"Rassidakis","year":"2009","journal-title":"Leukemia"},{"key":"33","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1158\/1535-7163.MCT-08-0391","article-title":"Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway","volume":"7","author":"Smalley","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"34","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1158\/1535-7163.MCT-14-0220","article-title":"andinteractions between the HDAC6 inhibitor ricolinostat (ACY1215) and the irreversible proteasome inhibitor carfilzomib in non-Hodgkin lymphoma cells","volume":"13","author":"Grant","year":"2014","journal-title":"Mol Cancer Ther"},{"key":"35","doi-asserted-by":"crossref","first-page":"e47361","DOI":"10.1371\/journal.pone.0047361","article-title":"Fusion toxin BLyS-gelonin inhibits growth of malignant human B cell linesand","volume":"7","author":"Humphreys","year":"2012","journal-title":"PLoS One"},{"key":"36","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/BJ20070797","article-title":"The selectivity of protein kinase inhibitors: a further update","volume":"408","author":"Cohen","year":"2007","journal-title":"Biochem J"},{"key":"37","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(12)70474-6","article-title":"Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study","volume":"13","author":"Vassilev","year":"2012","journal-title":"Lancet Oncol"},{"key":"38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nrd4236","article-title":"Drugging the p53 pathway: understanding the route to clinical efficacy","volume":"13","author":"Lane","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"39","doi-asserted-by":"crossref","first-page":"12594","DOI":"10.1021\/bi701096s","article-title":"The Wip1 phosphatase PPM1D dephosphorylates SQ\/TQ motifs in checkpoint substrates phosphorylated by PI3K-like kinases","volume":"46","author":"Appella","year":"2007","journal-title":"Biochemistry"},{"key":"40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Talalay","year":"1984","journal-title":"Adv Enzyme Regul"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11904","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T13:52:07Z","timestamp":1589291527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.11904"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,8]]},"references-count":40,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2016,10,25]]}},"alternative-id":["11904","27626308"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.11904","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,8]]}}}